Brepocitinib treatment for adults with lichen planopilaris

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2/3 randomized, placebo-controlled study gives eligible adults with biopsy-confirmed, active lichen planopilaris oral brepocitinib or placebo to measure clinical safety and symptom improvement. Participants must have active, symptomatic scalp disease at screening and meet weight/BMI limits, and will be followed over the treatment period with regular clinic visits. Key exclusions include recent or active malignancy, high risk of thrombosis or herpes zoster, and active or recent infections. The trial aims to compare efficacy outcomes and adverse events between brepocitinib and placebo groups to determine whether the drug provides measurable benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years
2. Scalp biopsy consistent with LPP
3. Active and symptomatic LPP at screening and baseline-
4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria:

1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

Where it's running

• Clinical Trial Site
  Birmingham, Alabama, United States Recruiting
• Clinical Trial Site
  Phoenix, Arizona, United States Recruiting
• Clinical Trial Site
  Scottsdale, Arizona, United States Recruiting
• Clinical Trial Site
  Irvine, California, United States Recruiting
• Clinical Trial Site
  Oakland, California, United States Recruiting
• Clinical Trial Site
  Sacramento, California, United States Recruiting

+11 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Clinical Trial Administrator
• Email: clinicaltrials@priovant.com
• Phone: (212) 634-9743

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Topical delgocitinib 2% cream for Lichen Planopilaris and Central Centrifugal Cicatricial Alopecia

  This trial tests whether applying 2% delgocitinib cream twice daily is safe and changes scalp biomarkers in adults with Lichen Planopilaris or Central Centrifugal Cicatricial Alopecia over 48 weeks.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07487948

• Evaluating Brepocitinib for Treating Skin Sarcoidosis

  This study tests if an oral medication called brepocitinib can help adults with skin sarcoidosis feel better compared to a placebo.

  Recruiting at 44 sites Phase 2/3 Priovant Therapeutics, Inc. · Birmingham, Alabama and 43 other locations · NCT06978725

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.